מקיניסט 2 מג
novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib
disposable non - woven protective products
עדי לין אול מדיק בע"מ - אחות - חלוקים, מסכות פנים, כיסויי ראש, כיסויי נעלים, כיסויי מיטות חד פעמיים לכול הצוות הרפואי
נבלבין 20 מג
padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.
נבלבין 30 מג
padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 30 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.
רינבוק 15 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib
רינבוק 15 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib
רינבוק 30 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 30 mg - upadacitinib
רינבוק 45 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 45 mg - upadacitinib
טרסבה 150 מג
roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.
טרסבה 100 מג
roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.